theory clinical_79_5
imports Main

begin

typedecl entity
typedecl event

consts
  Patient :: "entity ⇒ bool"
  TNBC :: "entity ⇒ bool"
  Immunotherapy :: "entity ⇒ bool"
  PARPInhibitors :: "entity ⇒ bool"
  AppropriateFor :: "entity ⇒ entity ⇒ bool"
  SecondLineTherapy :: "entity ⇒ bool"
  Combination :: "entity ⇒ bool"
  Vemurafenib :: "entity ⇒ bool"
  MEKInhibitor :: "entity ⇒ bool"
  AvailableFor :: "entity ⇒ entity ⇒ bool"
  Carboplatin :: "entity ⇒ bool"
  Paclitaxel :: "entity ⇒ bool"
  AdvancedMelanoma :: "entity ⇒ bool"
  BRAFV600 :: "entity ⇒ bool"
  Activity :: "entity ⇒ bool"
  Tolerated :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  Demonstrates :: "event ⇒ bool"
  PredominantlyIn :: "entity ⇒ entity ⇒ bool"
  IrrespectiveOfPriorTreatment :: "entity ⇒ entity ⇒ bool"
  Chemotherapy :: "entity ⇒ bool"
  TreatmentOutcomes :: "entity ⇒ bool"
  Benefit :: "event ⇒ bool"
  Improve :: "event ⇒ bool"
  SpecificallyFor :: "entity ⇒ entity ⇒ bool"
  TreatedWith :: "entity ⇒ entity ⇒ bool"
  BRAF :: "entity ⇒ bool"
  Source :: "event ⇒ entity ⇒ bool"

(* Explanation 1: Patient with TNBC is not appropriate for immunotherapy or PARP inhibitors as second line therapy *)
axiomatization where
  explanation_1: "∀x y z. Patient x ∧ TNBC x ∧ Immunotherapy y ∧ PARPInhibitors z ⟶ (¬AppropriateFor x y ∧ ¬AppropriateFor x z ∧ SecondLineTherapy x)"

(* Explanation 2: Combination vemurafenib and MEK inhibitor is unavailable for the patient *)
axiomatization where
  explanation_2: "∀x y z. Combination x ∧ Vemurafenib x ∧ MEKInhibitor x ∧ Patient y ⟶ ¬AvailableFor x y"

(* Explanation 3: The combination of vemurafenib, carboplatin, and paclitaxel is well tolerated and demonstrates encouraging activity, predominantly in patients with advanced melanoma and BRAFV600 mutations irrespective of prior treatment with BRAF and/or MEK inhibitors *)
axiomatization where
  explanation_3: "∃x y z w e1 e2. Combination x ∧ Vemurafenib x ∧ Carboplatin x ∧ Paclitaxel x ∧ Patient y ∧ AdvancedMelanoma y ∧ BRAFV600 y ∧ Activity z ∧ Tolerated e1 ∧ Agent e1 x ∧ Agent e1 y ∧ Demonstrates e2 ∧ Agent e2 x ∧ Agent e2 z ∧ PredominantlyIn y w ∧ IrrespectiveOfPriorTreatment y w"

(* Explanation 4: Combination of vemurafenib with chemotherapy, such as carboplatin and paclitaxel, benefits patients with advanced melanoma and BRAFV600 mutations by improving treatment outcomes, specifically for those who have not been treated with BRAF and/or MEK inhibitors *)
axiomatization where
  explanation_4: "∃x y z w e1 e2. Combination x ∧ Vemurafenib x ∧ Chemotherapy x ∧ Carboplatin x ∧ Paclitaxel x ∧ Patient y ∧ AdvancedMelanoma y ∧ BRAFV600 y ∧ TreatmentOutcomes z ∧ Benefit e1 ∧ Agent e1 x ∧ Agent e1 y ∧ Improve e2 ∧ Agent e2 x ∧ Agent e2 z ∧ SpecificallyFor y w ∧ ¬TreatedWith y w"

(* Explanation 5: The specific patient in question has advanced melanoma and BRAFV600 mutations and has not been treated with BRAF and/or MEK inhibitors *)
axiomatization where
  explanation_5: "∃x y z. Patient x ∧ AdvancedMelanoma x ∧ BRAFV600 x ∧ BRAF y ∧ MEKInhibitor z ∧ ¬TreatedWith x y ∧ ¬TreatedWith x z"

(* Explanation 6: This patient is expected to benefit from combination vemurafenib and chemotherapy *)
axiomatization where
  explanation_6: "∃x y e. Patient x ∧ Combination y ∧ Vemurafenib y ∧ Chemotherapy y ∧ Benefit e ∧ Agent e x ∧ Source e y"

theorem hypothesis:
  assumes asm: "Patient x ∧ Combination y ∧ Vemurafenib y ∧ Chemotherapy y"
  (* Hypothesis: Patient may benefit from combination vemurafenib and chemotherapy *)
  shows "∃x y e. Patient x ∧ Combination y ∧ Vemurafenib y ∧ Chemotherapy y ∧ Benefit e ∧ Agent e x ∧ Source e y"
  using explanation_6 by blast
  

end
